Yu Chen
Director/Board Member bij Genor Biopharma Co., Ltd.
Profiel
Yu Chen is currently a Director at Genor Biopharma Co., Ltd.
and PharmaLegacy Laboratories (Shanghai) Co., Ltd.
Previously, he held positions as a Director at Suzhou NanoMicro Technology Co. Ltd., GemPharmatech Co., Ltd., Genor Biopharma Holdings Ltd., and Zhaoke Ophthalmology Ltd.
He also worked as an Associate at Citigroup Global Markets Asia Ltd.
and as a Senior Manager-Investment at Shanghai Panxin Equity Investment Management Co. Ltd.
Mr. Chen received his graduate degree from Stanford University in 2008, his graduate degree from Yale University in 2005, and his undergraduate degree from The Hong Kong University of Science & Technology in 2003.
Actieve functies van Yu Chen
Bedrijven | Functie | Begin |
---|---|---|
Genor Biopharma Co., Ltd.
Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Director/Board Member | - |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Director/Board Member | 01-07-2021 |
Eerdere bekende functies van Yu Chen
Bedrijven | Functie | Einde |
---|---|---|
ZHAOKE OPHTHALMOLOGY LIMITED | Director/Board Member | 08-04-2024 |
GENOR BIOPHARMA HOLDINGS LIMITED | Director/Board Member | 02-01-2024 |
GEMPHARMATECH CO., LTD. | Director/Board Member | 04-04-2023 |
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Director/Board Member | 30-03-2022 |
Shanghai Panxin Equity Investment Management Co. Ltd. | Chief Investment Officer | 01-07-2015 |
Opleiding van Yu Chen
Stanford University | Graduate Degree |
Yale University | Graduate Degree |
The Hong Kong University of Science & Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
SUZHOU NANOMICRO TECHNOLOGY CO., LTD. | Commercial Services |
GEMPHARMATECH CO., LTD. | Health Technology |
ZHAOKE OPHTHALMOLOGY LIMITED | Health Technology |
GENOR BIOPHARMA HOLDINGS LIMITED | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Citigroup Global Markets Asia Ltd.
Citigroup Global Markets Asia Ltd. Investment Banks/BrokersFinance Citigroup Global Markets Asia Ltd. (CGMA) is a securities brokerage firm headquartered Hong Kong. They are a subsidiary of Citigroup Global Markets Hong Kong Holdings Ltd., ultimately owned by Citigroup, Inc. (NYSE: C) in the US. Formerly known as Citi Smith Barney, the firm was reorganized in 2008 when Citigroup combined their brokerage and private banking businesses. CGMA offers stock trading services to various institutional investors. | Finance |
Genor Biopharma Co., Ltd.
Genor Biopharma Co., Ltd. BiotechnologyHealth Technology Genor Biopharma Co., Ltd. engages in the manufacture and development of antibodies and related biological products. Its business scope includes research and development of monoclonal antibodies and biological products; research and development of instruments, equipment and reagents related to monoclonal antibodies and biological products; and wholesale, import and export of instruments, mechanical equipment, pharmaceutical equipment, and pharmaceutical intermediates. The company was founded on December 4, 2007 and is headquartered in Shanghai, China. | Health Technology |
Shanghai Panxin Equity Investment Management Co. Ltd. | |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Commercial Services |